A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide

Tara Gurung,1 Deepson S Shyangdan,1 Joseph Paul O’Hare,2 Norman Waugh1 1Warwick Evidence, 2Division of Metabolic and Vascular Health, Warwick Medical School, University of Warwick, Coventry, UK Background: Dulaglutide is a new, long-acting glucagon-like peptide analogue in the treatment of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gurung T, Shyangdan DS, O’Hare JP, Waugh N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/bc350032f4514bc8a491ff16d157897f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bc350032f4514bc8a491ff16d157897f
record_format	dspace
spelling	oai:doaj.org-article:bc350032f4514bc8a491ff16d157897f2021-12-02T00:24:13ZA novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide1178-7007https://doaj.org/article/bc350032f4514bc8a491ff16d157897f2015-08-01T00:00:00Zhttp://www.dovepress.com/a-novel-long-acting-glucagon-like-peptide-receptor-agonist-dulaglutide-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Tara Gurung,1 Deepson S Shyangdan,1 Joseph Paul O’Hare,2 Norman Waugh1 1Warwick Evidence, 2Division of Metabolic and Vascular Health, Warwick Medical School, University of Warwick, Coventry, UK Background: Dulaglutide is a new, long-acting glucagon-like peptide analogue in the treatment of type 2 diabetes. It is available in two doses, 0.75 and 1.5 mg, given by injection once weekly. This systematic review reports the effectiveness and safety of dulaglutide in type 2 diabetes in dual and triple therapy.Methods: MEDLINE, MEDLINE In-Process and Other Non-Indexed Citations, EMBASE, and conference abstracts were searched from 2005 to August 2014, and updated in January 2015. Company websites and references of included studies were checked for potentially relevant studies. European Medicines Agency and US Food and Drug Administration websites were searched.Results: Four trials were included. All were manufacturer-funded randomized controlled trials from the Assessment of Weekly Administration of Dulaglutide in Diabetes (AWARD) program. AWARD-1 compared dulaglutide 1.5 mg against exenatide 10 µg twice daily and placebo, AWARD-2 compared dulaglutide 0.75 and 1.5 mg against insulin glargine, AWARD-5 compared dulaglutide 0.75 and 1.5 mg against sitagliptin 100 mg and placebo, and AWARD-6 compared dulaglutide 1.5 mg against liraglutide 1.8 mg. The duration of follow-up in the trials ranged from 26 to 104 weeks. The primary outcome of all the included trials was change in HbA1c. At 26 weeks, greater HbA1c reductions were seen with dulaglutide than with twice daily exenatide (dulaglutide 1.5/0.75 mg: −1.5%/−1.3%; exe: 0.99%) and sitagliptin (1.5/0.75 mg −1.22%/−1.01%; sitagliptin: −0.6%). HbA1c change was greater with dulaglutide 1.5 mg (−1.08%) than with glargine (−0.63%), but not with dulaglutide 0.75 mg (−0.76%). Dulaglutide 1.5 mg was found to be noninferior to liraglutide 1.8 mg. More patients treated with dulaglutide achieved HbA1c targets of <7% and ≤6.5%. Reduction in weight was greater with dulaglutide than with sitagliptin and exenatide. Hypoglycemia was infrequent. The main adverse events were nausea, diarrhea, and vomiting.Conclusion: Dulaglutide is effective in the treatment of patients with type 2 diabetes but we need long follow-up data for safety concerns.Keywords: dulaglutide, glucagon-like peptide analogue, type 2 diabetes, effectiveness, glycemic controlGurung TShyangdan DSO’Hare JPWaugh NDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2015, Iss default, Pp 363-386 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Gurung T Shyangdan DS O’Hare JP Waugh N A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
description	Tara Gurung,1 Deepson S Shyangdan,1 Joseph Paul O’Hare,2 Norman Waugh1 1Warwick Evidence, 2Division of Metabolic and Vascular Health, Warwick Medical School, University of Warwick, Coventry, UK Background: Dulaglutide is a new, long-acting glucagon-like peptide analogue in the treatment of type 2 diabetes. It is available in two doses, 0.75 and 1.5 mg, given by injection once weekly. This systematic review reports the effectiveness and safety of dulaglutide in type 2 diabetes in dual and triple therapy.Methods: MEDLINE, MEDLINE In-Process and Other Non-Indexed Citations, EMBASE, and conference abstracts were searched from 2005 to August 2014, and updated in January 2015. Company websites and references of included studies were checked for potentially relevant studies. European Medicines Agency and US Food and Drug Administration websites were searched.Results: Four trials were included. All were manufacturer-funded randomized controlled trials from the Assessment of Weekly Administration of Dulaglutide in Diabetes (AWARD) program. AWARD-1 compared dulaglutide 1.5 mg against exenatide 10 µg twice daily and placebo, AWARD-2 compared dulaglutide 0.75 and 1.5 mg against insulin glargine, AWARD-5 compared dulaglutide 0.75 and 1.5 mg against sitagliptin 100 mg and placebo, and AWARD-6 compared dulaglutide 1.5 mg against liraglutide 1.8 mg. The duration of follow-up in the trials ranged from 26 to 104 weeks. The primary outcome of all the included trials was change in HbA1c. At 26 weeks, greater HbA1c reductions were seen with dulaglutide than with twice daily exenatide (dulaglutide 1.5/0.75 mg: −1.5%/−1.3%; exe: 0.99%) and sitagliptin (1.5/0.75 mg −1.22%/−1.01%; sitagliptin: −0.6%). HbA1c change was greater with dulaglutide 1.5 mg (−1.08%) than with glargine (−0.63%), but not with dulaglutide 0.75 mg (−0.76%). Dulaglutide 1.5 mg was found to be noninferior to liraglutide 1.8 mg. More patients treated with dulaglutide achieved HbA1c targets of <7% and ≤6.5%. Reduction in weight was greater with dulaglutide than with sitagliptin and exenatide. Hypoglycemia was infrequent. The main adverse events were nausea, diarrhea, and vomiting.Conclusion: Dulaglutide is effective in the treatment of patients with type 2 diabetes but we need long follow-up data for safety concerns.Keywords: dulaglutide, glucagon-like peptide analogue, type 2 diabetes, effectiveness, glycemic control
format	article
author	Gurung T Shyangdan DS O’Hare JP Waugh N
author_facet	Gurung T Shyangdan DS O’Hare JP Waugh N
author_sort	Gurung T
title	A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
title_short	A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
title_full	A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
title_fullStr	A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
title_full_unstemmed	A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
title_sort	novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/bc350032f4514bc8a491ff16d157897f
work_keys_str_mv	AT gurungt anovellongactingglucagonlikepeptidereceptoragonistdulaglutide AT shyangdands anovellongactingglucagonlikepeptidereceptoragonistdulaglutide AT oharejp anovellongactingglucagonlikepeptidereceptoragonistdulaglutide AT waughn anovellongactingglucagonlikepeptidereceptoragonistdulaglutide AT gurungt novellongactingglucagonlikepeptidereceptoragonistdulaglutide AT shyangdands novellongactingglucagonlikepeptidereceptoragonistdulaglutide AT oharejp novellongactingglucagonlikepeptidereceptoragonistdulaglutide AT waughn novellongactingglucagonlikepeptidereceptoragonistdulaglutide
_version_	1718403762338398208

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide

Ejemplares similares